Clinical Trials Logo

Esophagus Cancer, Adenocarcinoma clinical trials

View clinical trials related to Esophagus Cancer, Adenocarcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT05069766 Completed - Clinical trials for Esophagus Cancer, Adenocarcinoma

Preoperative Marking of the Oral Resection Margin in Esophageal Cancer With a Surgical Fiducial Marker - First Experiences

Start date: September 1, 2021
Phase: N/A
Study type: Interventional

This study aims to evaluate if BioXmark™, a surgical marker, may efficiently and safely be used to preoperatively mark the proximal and distal resection line 5 cm proximal and distal to the tumor margin of gastroesophageal-junction adenocarcinoma (GEJ AC). Furthermore, to determine if placing the resection margin according to the resection margin defined by BioXmark™ is superior to the current standard of a proximal resection line estimation by the individual surgeon based on the intraoperative findings.

NCT ID: NCT04669951 Completed - Clinical trials for Esophagus Cancer, Adenocarcinoma

Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Cancer

Start date: November 18, 2019
Phase: N/A
Study type: Interventional

The aim of this study is to investigate urokinase Plasminogen Activator Receptor (uPAR) microexpression in gastroesophageal cancer (adenocarcinomas) both qualitatively and semi-quantitatively and to evaluate if it offers a possibility for future imagining purposes.

NCT ID: NCT03995017 Active, not recruiting - Clinical trials for Esophagus Cancer, Adenocarcinoma

Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma

RiME
Start date: January 9, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The study population is advanced gastric, gastroesophageal, and esophageal adenocarcinoma participants who have failed upfront standard of care chemotherapy. The goal is to demonstrate that Rucaparib plus Ramucirumab with or without Nivolumab has a higher response rate than what has been reported for Ramucirumab in previously treated patients. Trial will be a phase 1/2 trial. The Phase 1 portion will determine the recommended Phase 2 treatment dose for the combination of Rucaparib plus Ramucirumab and Nivolumab and enroll approximately 6-9 participants. The Phase 2 portion of the study will involve 52 participants allocated between two treatment groups comparing Rucaparib plus Ramucirumab with or without Nivolumab. The participants will be selected based on the results of a screening HRD gene panel.